Biopsy Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Biopsy Devices Market Trends and Insights

Rising Demand For Minimally Invasive Cancer Diagnostics

Nanoneedle patches developed at King’s College London allow painless tissue sampling by inserting millions of micro-needles that are 1,000 times thinner than human hair, enabling real-time monitoring without tissue damage. Parallel advances in pneumatically driven robotic catheters achieve six-direction sampling inside tortuous luminal organs, cutting procedure time and improving patient comfort. Clinics therefore increasingly favor less invasive hardware that minimizes complications and yields high-quality specimens, a key catalyst for the biopsy devices market worldwide. Health-system purchasers also note lower downstream costs from shorter recovery times and fewer repeat procedures, reinforcing adoption. As these technologies mature, suppliers that integrate robotic actuation and micro-sampling into cohesive platforms are gaining a competitive edge.

Growing Incidence Of Hard-To-Reach Organ Cancers

Lung cancer remains the world’s top cause of cancer mortality, representing 18.7% of global cancer deaths in 2024^{[1]World Health Organization, “Global cancer burden growing, amidst mounting need for services,” who.int}. The anatomical obstacles of accessing lungs, pancreas, and brain heighten demand for precision needles, steerable catheter systems, and advanced imaging accessories. High-income nations report the greatest disease burden, yet emerging markets are witnessing rapid incidence growth without equivalent diagnostic capacity. Hospitals are therefore upgrading to image-guided core and vacuum-assisted devices that improve sampling accuracy and shorten anesthesia time—an investment pattern that sustains the biopsy devices market even as reimbursement regimes tighten.

AI-Enabled Image Guidance Improves First-Pass Yield

Perimeter Medical Imaging AI won FDA review for its B-Series OCT system that reduces re-excision rates in breast-conserving surgery by mapping margins intra-operatively. Clairity’s breast-risk platform and Olympus’s CADDIE colonoscopy software likewise secure U.S. clearances, showing regulators’ willingness to fast-track algorithms that enhance accuracy. In June 2025 the FDA published draft guidance outlining performance-monitoring, bias mitigation, and post-market expectations for AI devices, giving manufacturers clearer routes to approval. Early adopters see measurable gains in first-pass success, procedure time, and staff productivity, accelerating integration across radiology and operating rooms.

Expansion Of Government-Funded Screening Programs

Australia’s National Lung Cancer Screening Program, launched July 2025, offers bulk-billed low-dose CT for high-risk adults aged 50-70 and is expected to lift early-stage detection from 16% to 60%^{[2]Australian Government Department of Health, “About the National Lung Cancer Screening Program,” health.gov.au}. The country also lowered bowel-screening eligibility to 45 years in 2024, widening the pool of positive findings that require tissue confirmation. In the United States, the National Cancer Institute’s new Screening Research Network will enroll up to 24,000 volunteers to test emerging multi-cancer assays. These initiatives funnel large screening cohorts into diagnostic pathways, lifting procedure volumes and ensuring recurring demand for biopsy instruments.

Device Recalls & Sterility-Failure Events

Olympus withdrew single-use lung-biopsy sheaths after detachable tips caused 26 serious injuries, compelling hospitals to quarantine stock and reschedule procedures. Hologic’s Class I recall of 53,492 BioZorb markers followed reports of pain, infection, and migration. Cardinal Health likewise pulled biopsy-related procedure kits over sterility concerns. Such events intensify regulatory scrutiny, force costly remediation programs, and can dampen clinician confidence, thereby restraining near-term growth for the biopsy devices market.

Competition From Liquid-Biopsy Technologies

Circulating tumor DNA assays offer painless, repeatable sampling for tumor monitoring and are gaining clinical traction. The National Cancer Institute is funding validation studies, and companies such as Guardant Health and Thermo Fisher are expanding assay menus, putting price and performance pressure on traditional biopsy devices. Device manufacturers must therefore differentiate through accuracy, margin assessment, and integration with molecular-profiling workflows to defend share.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product: Needle-Based Systems Drive Innovation

Needle-based instruments generated USD 0.99 billion of revenue in 2025, equal to 44.20% of the biopsy devices market size, and they are forecast to clock an 8.12% CAGR through 2031. Core and vacuum-assisted models integrate electromagnetic tracking and AI analytics that highlight suspicious tissue in real time, cutting the learning curve for less-experienced operators. Elucent Medical’s EnVisio X1 earned FDA breakthrough status for combining optical navigation with radiofrequency-guided depth control, underscoring the investment arms race around precision targeting. In parallel, disposable needle cartridges align with infection-control mandates and accelerate turnover in ambulatory theatres, helping the biopsy devices market penetrate lower-acuity settings.

Procedure trays register steady gains because standardized kits streamline set-up and lower costs per case, an advantage prized by outpatient facilities under bundled-payment models. Localization wires remain a breast-care staple, yet newer clip-based markers that dissolve or emit low-energy radar signals are gradually cannibalizing demand by improving patient comfort and eliminating retrieval steps. Supporting accessories such as cannulas, obturators, and vacuum tubing now feature RFID tags that automate lot tracking and simplify recall management, a response to recent sterility failures.

By Application: Lung Procedures Accelerate Growth

Breast applications retained 31.12% of the biopsy devices market share in 2025 on the back of mammography-driven screening pathways and well-rehearsed surgical protocols. Yet lung procedures are projected to register a 9.02% CAGR, outpacing every other use-case through 2031. Australia’s publicly funded lung program and similar pilots in the United States and South Korea are redirecting large cohorts of CT-screen-detected nodules to bronchoscopy suites, lifting demand for steerable needles and electromagnetic navigation catheters. Suppliers that combine radial ultrasound, thin-gauge biopsy, and real-time pathology imaging are capturing early adopters.

Colorectal procedures benefit from expanded screening ages and AI-enabled colonoscope add-ons that flag polyps, increasing tissue-sampling events per colonoscopy. Prostate applications pivot toward MRI-fusion guidance, using transperineal access and vacuum-assisted cores to raise cancer detection and cut infection. Other applications such as pancreatic, liver, and renal biopsies see incremental uptake as hospitals invest in endoscopic ultrasound and intravascular robotics to reach previously inaccessible lesions, strengthening the long-tail of the biopsy devices market.

By End-User: Ambulatory Centers Emerge As Growth Engine

Hospitals handled 68.15% of procedures in 2025 and continue to buy high-throughput biopsy platforms, particularly those that integrate AI decision-support with PACS and electronic health records for immediate multidisciplinary review. However, ambulatory surgical centers are forecast to deliver a 9.18% CAGR, leveraging lower overhead and shorter stay times to backfill elective surgeries that shifted away from hospitals during the pandemic. Developers that supply compact vacuum-assisted consoles, sterile single-use needles, and tray-based component kits gain traction because capital budgets in these centers favor modular, pay-per-use models.

Diagnostic imaging centers keep broadening service lines by adding ultrasound-guided fine-needle aspiration and CT-guided core biopsy, capitalizing on portable scanners that fit within existing floor plans. Specialty clinics and mobile units form a small but rising share as governments fund outreach to rural districts, especially in Asia-Pacific nations where unmet need remains high. Collectively, these trends reinforce the diffusion of the biopsy devices market beyond tertiary campuses into community settings.

Geography Analysis

North America captured 41.25% of 2025 revenue owing to robust insurance coverage, technology-minded clinicians, and well-defined reimbursement pathways, cementing the region’s anchor position in the global biopsy devices market. Continuous innovation—illustrated by AI-assisted OCT, robotic bronchoscopy, and ultrathin flexible needles—ensures a steady refresh cycle for capital equipment. Nevertheless, hospitals face payer scrutiny over procedure bundles, nudging facilities toward cost-effective disposables and predictive analytics that prune unnecessary sampling.

Europe records modest but stable gains as national health systems emphasize value-based purchasing and personalized medicine. Uptake of markers that aid in margin assessment and molecular assays that guide targeted therapy is noticeable, spurring EU demand for high-quality tissue retrieval. Regulatory alignment under the Medical Device Regulation has lengthened approval timelines, but clear clinical-benefit documentation offsets the bureaucratic burden.

Asia-Pacific is projected to log an 8.25% CAGR through 2031, by far the fastest cadence for the biopsy devices market. India’s USD 612 billion health-sector build-out, China’s expansion of tier-2 oncology centers, and Southeast Asia’s private hospital boom enlarge the addressable install base. Governments simultaneously roll out lung, bowel, and cervical screening policies that feed procedure pipelines. Domestic manufacturers are emerging, yet premium U.S., Japanese, and European brands maintain technical leadership in vacuum and image-guided systems.

The Middle East, Africa, and South America account for smaller shares but show selective spikes where public-private partnerships fund cancer hubs. In the Gulf, large specialty hospitals procure top-tier biopsy suites tied to comprehensive oncology campuses. In Brazil and Mexico, reimbursement reforms encourage private insurers to cover advanced biopsy techniques, incrementally widening the patient pool. Supply-chain challenges and variable regulatory oversight temper immediate gains, but multinationals are positioning via local assembly and distribution alliances to unlock future growth.

Market Opportunities and Future Outlook

Technology whitespace is widening around image-guided, workflow-integrated tissue acquisition, especially for breast and lung pathways where hospitals and outpatient centers want fewer repeats and faster room turnover. In 2026, major device developers advanced single-use biopsy tools and MR-compatible integrated systems, including BD EnCor EnCompass breast biopsy and tissue removal system (FDA 510(k) clearance in January 2026), Mammotome Prima MR in-room MRI vacuum-assisted breast biopsy system (FDA clearance in March 2026), and Promisemed VeriEcto automatic biopsy needles (510(k) clearance in May 2026). These steps broaden options for bundled sampling tools with real-time guidance and in-room, MR-compatible workflows that can fit within existing endoscopy and radiology suites.

Breast biopsy remains a key platform opportunity tied to MRI and contrast workflows, as facilities look for in-room capability and streamlined lesion targeting under advanced imaging. The 2026 clearances point to continued investment in integrated consoles and single-workflow biopsy systems, which can support faster clinical decision-making and fewer repeat procedures in both hospital and ambulatory settings.